Sugi Predict

Sugi Predict / Compounds / SCHEMBL6562939

SCHEMBL6562939

SCHEMBL6562939

CC(C)C[C@H](NC(=O)C1CCCCC1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ PSMB5 P28074 5/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ MAPT P10636 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ FOLH1 Q04609 2/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9829273 1.00 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL8581694 1.00 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL7896986 1.00 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL6561332 0.98 TSHR (0.53) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL7897832 0.98 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL9832137 0.98 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1LMNATSHR
Benzene SCHEMBL28226142 0.97 PSMB5 (0.55) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL25045739 0.95 KMT2A (0.56) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL7898545 0.94 SMN1; SMN2 (0.54) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL6562866 0.93 SMN1; SMN2 (0.53) ALDH1A1KMT2AMEN1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040062773-A1 Compositions for the delivery of antigens EMISPHERE TECHNOLOGIES INC. 2004-04-01 — — US claimed
EP-0784469-B1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECH INC (US) 2004-03-24 — — EP claimed
US-6610329-B2 Using acylated amino acid as carrier EMISPHERE TECHNOLOGIES INC. 2003-08-26 — — US claimed
US-20020001591-A1 Compositions for the delivery of antigens EMISPHERE TECHNOLOGIES, INC. 2002-01-03 — — US claimed
US-5958457-A MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS EMISPHERE TECHNOLOGIES, INC. (US) 1999-09-28 — — US claimed
EP-0784469-A4 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECH INC (US) 1999-03-24 — — EP claimed
EP-0784469-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS Emisphere Technologies, Inc. (US) 1997-07-23 — — EP claimed
WO-1996012474-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-05-02 — — WO claimed
EP-4701624-A1 NEW EPITHELIAL PERMEATION ENHANCER ROQUETTE FRERES (FR) 2026-03-04 — — EP disclosed
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARM INC (US) 2026-02-05 — — US disclosed
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-08-05 — — US disclosed
EP-3615019-B1 MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION NAVITOR PHARM INC (US) 2025-06-04 — — EP disclosed
EP-4556069-A2 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2025-05-21 — — EP disclosed
WO-1996021464-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-07-18 — — WO disclosed
WO-1996012474-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-05-02 — — WO disclosed
WO-1995028838-A1 MODIFIED AMINO ACIDS FOR DRUG DELIVERY EMISPHERE TECHNOLOGIES, INC. (US) 1995-11-02 — — WO disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 — — EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 — — US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF RICTOR, RPTOR, MTOR ALDH1A1 3529/4885KMT2A 1343/4885MEN1 2000/4885
US-20020001591-A1 Compositions for the delivery of antigens CD47, CD74, LY96 ALDH1A1 4355/4885KMT2A 1910/4885MEN1 4006/4885
US-20040062773-A1 Compositions for the delivery of antigens CD47, CD74, LY96 ALDH1A1 4355/4885KMT2A 1910/4885MEN1 4006/4885
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 ALDH1A1 3585/4885KMT2A 1672/4885MEN1 2509/4885
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 ALDH1A1 3585/4885KMT2A 1672/4885MEN1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.